Anixa Biosciences
ANIX
45 hedge funds and large institutions have $9.95M invested in Anixa Biosciences in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 7 closing their positions.
236% more call options, than puts
Call options by funds: $151K | Put options by funds: $45K
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
10% more capital invested
Capital invested by funds: $9.05M → $9.95M (+$892K)
10% more funds holding
Funds holding: 41 → 45 (+4)
0.23% less ownership
Funds ownership: 10.96% → 10.73% (-0.23%)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$158K |
| 2 |
GAM
Gemmer Asset Management
Walnut Creek,
California
|
+$110K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$76.6K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$76.4K |
| 5 |
LPL Financial
San Diego,
California
|
+$69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$438K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$80K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$42.4K |
| 4 |
US Bancorp
Minneapolis,
Minnesota
|
-$41.8K |
| 5 |
Morgan Stanley
New York
|
-$40.5K |
ANIX Hedge Fund Activity: Q2 2022 in Review
45 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q2 2022, worth a combined $9.95M — up 9.9% from $9.05M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ANIX positions and 7 closed out — a net gain of 4 holders — while 8 added to existing stakes and 11 trimmed.
The largest buyer was Long Focus Capital Management, adding an estimated $158K. The largest seller was Renaissance Technologies, cutting an estimated $438K.
- 45 institutional investors held Anixa Biosciences (ANIX) as of Q2 2022, up from 41 in Q1 2022.
- Funds reported $9.95M of Anixa Biosciences stock for Q2 2022, up 9.9% quarter-over-quarter.
- 11 funds opened new Anixa Biosciences positions in Q2 2022 and 7 closed out, a net change of +4 holders.
- The largest Anixa Biosciences buyer in Q2 2022 was Long Focus Capital Management, an estimated $158K added.
- The largest Anixa Biosciences seller in Q2 2022 was Renaissance Technologies, an estimated $438K sold.
Based on aggregated 13F filings for Q2 2022.